Over one billion people live with a mental health condition. Mental health disorders are the second leading cause of disability worldwide, and depression and anxiety alone cost the global economy over $1 trillion a year. Yet the standard of care for patients has remained largely unchanged for over fifty years.

Mental health innovation is at an inflection point. Novel therapies, including next-generation psychedelics, are advancing through late-stage clinical trials with unprecedented efficacy data. Multiple programs have received FDA Breakthrough Therapy Designation, with significant and durable symptom reduction demonstrated across depression, PTSD, and women's mental health. After decades of stagnation in mental health drug development, a new wave of treatments is redefining hope for patients.

Palo Santo invests across the neuroscience and mental health landscape, with a focus on novel CNS therapeutics and technologies that have the potential to transform patient outcomes and accelerate precision neuroscience. Our portfolio spans neurological therapeutics, next-generation psychedelic therapies, and technologies at the forefront of brain health innovation. Our team brings decades of experience in neuroscience, biotech operations, investing, and clinical development, supported by leading academics and scientific advisors at the frontier of the field.